Acumen Pharmaceuticals, Inc.
ABOS · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $47 | $37 | $30 | $36 |
| Short-Term Investments | $80 | $107 | $119 | $136 |
| Receivables | $0 | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 |
| Other Curr. Assets | $5 | $5 | $5 | $7 |
| Total Curr. Assets | $132 | $148 | $155 | $178 |
| Property Plant & Equip (Net) | $0 | $0 | $0 | $0 |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangibles | $0 | $0 | $0 | $0 |
| Long-Term Investments | $9 | $23 | $49 | $60 |
| Tax Assets | $0 | $0 | $0 | $0 |
| Other NC Assets | $0 | $0 | $0 | $0 |
| Total NC Assets | $10 | $23 | $50 | $61 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $142 | $172 | $204 | $239 |
| Liabilities | – | – | – | – |
| Payables | $1 | $2 | $1 | $6 |
| Short-Term Debt | $4 | $0 | $0 | $0 |
| Tax Payable | $0 | $0 | $0 | $0 |
| Deferred Revenue | $0 | $0 | $0 | $0 |
| Other Curr. Liab. | $18 | $23 | $18 | $22 |
| Total Curr. Liab. | $22 | $25 | $19 | $28 |
| LT Debt | $27 | $30 | $29 | $30 |
| Deferred Rev, NC | $0 | $0 | $0 | $0 |
| Deferred Tax Liab, NC | $0 | $0 | $0 | $0 |
| Other NC Liab. | $0 | $0 | $1 | $0 |
| Total NC Liab. | $27 | $30 | $30 | $30 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $0 | $0 | $0 | $0 |
| Total Liabilities | $49 | $55 | $49 | $57 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $0 |
| Common Stock | $0 | $0 | $0 | $0 |
| Retained Earnings | -$421 | -$395 | -$354 | -$325 |
| AOCI | $0 | $0 | $0 | -$0 |
| Other Equity | $514 | $512 | $509 | $507 |
| Total Equity | $93 | $117 | $156 | $182 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $142 | $172 | $204 | $239 |
| Net Debt | -$16 | -$7 | -$1 | -$6 |